Melanocortin Obesity SyndromePhase 2MCOSNCT06899178
Atomoxetine in Melanocortin Obesity Syndrome
A Phase 2 study testing Atomoxetine in people with Melanocortin Obesity Syndrome and MCOS, run by Icahn School of Medicine at Mount Sinai at 3 sites in United States.
Trial summary
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders. Read more about this study
- Who is it for?
- Ages 6 years and older
- Conditions the study is for
- Melanocortin Obesity Syndrome, MCOS
- What is being tested?
- Atomoxetine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Sep 2026to Jun 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age 6 years and above
- Documented MC4R variant classified as pathogenic, likely pathogenic, or variant of uncertain significance per ACMG criteria. If testing was done in a research lab, it will be confirmed by a CLIA-approved lab prior to randomization.
- Obesity defined as BMI ≥30 kg/m2 in adults or ≥95th percentile for age and sex in children
Who cannot join
- Use of atomoxetine, viloxazine (another selective norepinephrine-reuptake inhibitor), methylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, phentermine, or any other stimulant medication in the past 30 days. If on other ADHD medications, such as guanfacine and clonidine, must be on a stable dose for >3 months.
- Weight loss >5% in the past 3 months.
- Initiation of new weight loss program, including diet or medications. If on weight loss medications, must be on a stable dose for >3 months.
- Inability to swallow capsules.
- History of hypersensitivity to atomoxetine.
- Narrow angle glaucoma.
Show all 16Show fewer
- History of pheochromocytoma.
- Uncontrolled Stage 2 hypertension (≥95th percentile + 12 mmHg or >140/90, whichever is lower) at screening. If on antihypertensive medication, must be on stable dose for >3 months.
- Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT >3x upper limit of normal)
- Uncontrolled asthma requiring albuterol more than once weekly over the past 3 months
- History of a cardiac arrhythmia (not including bradycardia)
- Current use of monoamine oxidase inhibitors
- Pregnancy or intention to become pregnant during the next year
- History of Major Depressive Disorder in the past 2 years, lifetime history of suicide attempt, history of any suicidal behavior in the past month, history of other severe psychiatric disorders (e.g. schizophrenia, bipolar disorder)
- PHQ-9 score is ≥15 or suicidal ideation of type 4 or 5 (C-SSR) in the past month
- Unable to comply with study procedures in the opinion of the investigator
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Not yet recruiting
Nationwide Children's Hospital
Columbus, Ohio, 43205
Joan Han, MD, 614-722-4170, joan.han@nationwidechildrens.org
Joan Han, MD
- Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Jenny Leshko, RN, 615-343-8116, jenny.leshko@vumc.org
Ashley Shoemaker, MD, MSCI, 615-343-8116, ashley.h.shoemaker@vumc.org
- Recruiting
Mount Sinai Hospital
New York, New York, 10029
Joan Han, MD, 212-241-3744, joan.han@mountsinai.org
Joan Han
About this study
Official title: A Phase 2, Double Blind, Randomized, Placebo-controlled Crossover Trial to Evaluate the Efficacy and Safety of Atomoxetine in Adults With Melanocortin Obesity Syndrome
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders. Atomoxetine was selected for this pilot trial because it has been shown to increase brain-derived neurotrophic factor (BDNF) within the central nervous system and in peripheral circulation. Targeting BDNF is a specific strategy for treating MC4R abnormalities because BDNF functions as a downstream mediator of MC4R signaling.
Read the detailed description
Targeted therapies for the treatment of monogenetic obesity are essential because typical lifestyle interventions and standard anti-obesity medications are largely ineffective as they do not correct the specific genetic defect causing abnormal energy balance. The leptin pathway is the key regulator of body weight through control of appetite and energy expenditure. In particular, the severe insatiable hunger experienced by patients with leptin pathway disorders leads not only to extreme obesity, but the unrelenting drive to seek food also causes substantial distress for patients and caregivers. While therapies have been developed for treating genetic disorders affecting the proximal portion of the leptin pathway (LEP, LEPR, POMC, PCSK1, and BBS1-22), there are no treatments for loss-of-function LOF) variants of the melanocortin-4 receptor gene (MC4R), which cause melanocortin obesity syndrome (MCOS). In various population and cohort studies, 1-6% of patients with severe, early onset obesity are found to have MC4R LOF variants, making MCOS the most common cause of genetic obesity. Brain-derived neurotrophic factor (BDNF) is a downstream mediator of MC4R signaling and, therefore, may serve as a specific target for MCOS treatment. The researchers propose repurposing a well-understood and commercially available attention-deficit hyperactive disorder (ADHD) medication, atomoxetine (FDA-approved for the treatment of ADHD in persons ages 6 years and older), for the treatment of MCOS because of animal and human studies show that this drug induces endogenous BDNF levels. Atomoxetine could potentially increase hypothalamic BDNF levels, leading to weight loss through improved anorectic signaling downstream of the abnormally functioning MC4R. A phase 2 randomized, placebo-controlled crossover trial in 20 patients with MCOS will be conducted to test this hypothesis. The study will begin in adult patients and if safety and efficacy are shown, then pediatric patients age ≥ 6 years will be studied. The primary outcome measure will be change in BMI (expressed as the percentage of the 95th percentile BMI for age/sex). Additional measures will include percent body fat and visceral fat area by bioelectrical impedance analysis, resting energy expenditure by indirect calorimetry, dietary intake by food frequency questionnaire and 24-hour recall, hyperphagia score, hunger level, satiety level, hemoglobin A1c, lipid panel, liver function tests, blood pressure, heart rate, and ADHD symptoms. Serum and plasma BDNF and genetic variants in atomoxetine metabolism enzymes will be assessed and correlated with weight changes. This pilot clinical trial will provide valuable data on the safety and efficacy of atomoxetine for treating MCOS, and the data will be used to guide the design of a future phase 3, multicenter, randomized clinical trial.
- Conditions
- Melanocortin Obesity Syndrome, MCOS
- Being tested
- Atomoxetine, Placebo
- Keywords
- Obesity, BDNF, MC4R, Atomoxetine, Energy balance, Weight loss
- Medical subject headings
- Obesity, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtomoxetineDrug
Initial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose)
PlaceboDrug
Matching placebo oral capsule
| Study group | Role | What they receive |
|---|---|---|
| Placebo then Atomoxetine | Placebo comparator | Participants receive placebo for 16 weeks (4 weeks titration + 12 weeks at target dose), followed by washout period, then atomoxetine for 16 weeks (4 weeks titration + 12 weeks at target dose). Receives: Drug: Atomoxetine; Drug: Placebo |
| Atomoxetine then Placebo | Active comparator | Participants receive atomoxetine for 16 weeks (4 weeks titration + 12 weeks at target dose), followed by washout period, then placebo for 16 weeks (4 weeks titration + 12 weeks at target dose). Receives: Drug: Atomoxetine; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body Mass Index (BMI)
BMI will be calculated as kg/sq m. The sex appropriate CDC growth chart will be used to calculate BMI as a percent of the 95th percentile (BMI95). For patients >20 years, the 20-year-old percentiles will be used.
Measured: 16 weeks
Secondary outcomes (12)
Resting Energy Expenditure (REE)
Resting energy expenditure (REE) will be measured by indirect calorimetry after a minimum 1 hour of rest in the Clinical Research Center. Oxygen consumption and carbon dioxide production will be measured. The first 5-10 minutes of data will be discarded to allow participants to adjust to the metabolic cart.
Measured: 16 weeks
Healthy Eating Index (HEI)
The VioScreen assessment provides a Healthy Eating Index (HEI) score to measure the quality of a person's diet. The HEI score ranges from 0 to 100, with higher scores indicating better eating habits.
Measured: 16 weeks
Hyperphagia Questionnaire (HQ)
Hyperphagia will be assessed with the Hyperphagia Questionnaire (HQ)
This is a 13-item questionnaire with each question answered on a 5-point scale. Two of the questions are qualitative.
Full range is scored from 11 to 55. Higher score indicates greater hyperphagia.
Measured: 16 weeks
Hunger and Satiety Score
Full range scored from 0 to 10 with higher score indicating greater hunger/satiety.
Measured: 16 weeks
Fasting Glucose Level
A blood sugar test measures the amount of a sugar called glucose in a sample of blood.
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
Alanine Transaminase (ALT) Level
The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
Fasting Insulin Level
The insulin level in blood. Insulin is a hormone produced by beta cells in the pancreas.
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
Hemoglobin A1c
A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well blood sugar is controlled to help prevent complications from diabetes.
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
Lipid Panel - Fasting LDL, HDL, Triglycerides
A lipid profile is a blood test to measure different types of lipids:
High-density lipoprotein cholesterol (HDL [good] cholesterol): HDL helps remove LDL from your blood.
Low-density lipoprotein cholesterol (LDL [bad] cholesterol): LDL can build up in your blood vessels and increase your heart disease risk.
Triglycerides: Your body makes some triglycerides. Triglycerides also come from the food you eat. Extra calories are turned into triglycerides and stored in fat cells for later use.
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
High Sensitivity C-Reactive Protein
C-reactive protein (CRP) is produced by the liver. The level of CRP rises when there is inflammation in the body. It is one of a group of proteins, called acute phase reactants that go up in response to inflammation. The levels of acute phase reactants increase in response to certain inflammatory proteins called cytokines. These proteins are produced by white blood cells during inflammation.
The CRP test is a general test to check for inflammation in the body. It is not a specific test. A high-sensitivity C-reactive protein (hs-CRP) is a more A more sensitive CRP test
Fasting laboratory studies will be obtained at week 0, week 16 and week 32.
Measured: At week 0, week 16 and week 32.
The ASEBA Brief Problem Monitor
The ASEBA Brief Problem Monitor (BPM) is a quick assessment tool designed to monitor and track a child's behavioral and emotional problems over time, particularly focusing on internalizing, externalizing, and attention issues.
Range is 0 to 99.9th percentile
Measured: 16 weeks
Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist.
This is an 18-item self-report questionnaire designed for individuals to assess their own symptoms of Attention Deficit Hyperactivity Disorder (ADHD) focusing on daily experiences related to attention, impulsivity, and hyperactivity. Total scale is scored 0-72 with higher score indicating more predictive of an ADHD diagnosis.
Measured: 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2025
- Study start1 Sep 2026 (estimated)
- Primary completionMar 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Melanocortin Obesity SyndromeStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- A randomized, placebo-controlled, crossover study of atomoxetine. The treatment periods will last 16 weeks, separated by a 2-week washout period. Atomoxetine immediate release is approved for treatment of ADHD in children and adults. Enrollment will be based on age groups in batches, beginning with 10 adults, to optimize the protocol and monitor safety/efficacy before treating younger patients. If safety and efficacy are acceptable, the pediatric cohort will be enrolled. The intervention length of 16 weeks per arm was chosen to allow for 4 weeks of dose titration and 12 weeks exposure to target dose. The FDA effectiveness threshold for anti-obesity medication is 5% weight loss after 12 weeks. The half-life of atomoxetine is approximately 5 hours. A two-week washout period will allow for elimination of study drug while minimizing participant burden from frequent study visits.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Collaborators
- Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Responsible party
- Principal investigator, Joan Han, Icahn School of Medicine at Mount Sinai
- Investigators
- Joan C Han, MD, Principal investigator, Mount Sinai Kravis Children's HospitalAshley H Shoemaker, MD, MSCI, Principal investigator, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06899178
- Sponsor's protocol ID
- GCO 24-0669
- Other IDs
- 1R01DK142434-01
- Acronym
- MCOS
- Status last verified
- Aug 2026
- First submitted
- 21 Mar 2025
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Double Blind, Randomized, Placebo-controlled Crossover Trial to Evaluate the Efficacy and Safety of Atomoxetine in Adults With Melanocortin Obesity Syndrome
- ClinicalTrials.gov ID
- NCT06899178
- Acronym / sponsor ID
- MCOS / GCO 24-0669
- Conditions
- Melanocortin Obesity Syndrome, MCOS
- Keywords
- Obesity, BDNF, MC4R, Atomoxetine, Energy balance, Weight loss
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Collaborators
- Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 27 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders. Atomoxetine was selected for this pilot trial because it has been shown to increase brain-derived neurotrophic factor (BDNF) within the central nervous system and in peripheral circulation. Targeting BDNF is a specific strategy for treating MC4R abnormalities because BDNF functions as a downstream mediator of MC4R signaling.
Detailed description
Targeted therapies for the treatment of monogenetic obesity are essential because typical lifestyle interventions and standard anti-obesity medications are largely ineffective as they do not correct the specific genetic defect causing abnormal energy balance. The leptin pathway is the key regulator of body weight through control of appetite and energy expenditure. In particular, the severe insatiable hunger experienced by patients with leptin pathway disorders leads not only to extreme obesity, but the unrelenting drive to seek food also causes substantial distress for patients and caregivers. While therapies have been developed for treating genetic disorders affecting the proximal portion of the leptin pathway (LEP, LEPR, POMC, PCSK1, and BBS1-22), there are no treatments for loss-of-function LOF) variants of the melanocortin-4 receptor gene (MC4R), which cause melanocortin obesity syndrome (MCOS). In various population and cohort studies, 1-6% of patients with severe, early onset obesity are found to have MC4R LOF variants, making MCOS the most common cause of genetic obesity. Brain-derived neurotrophic factor (BDNF) is a downstream mediator of MC4R signaling and, therefore, may serve as a specific target for MCOS treatment. The researchers propose repurposing a well-understood and commercially available attention-deficit hyperactive disorder (ADHD) medication, atomoxetine (FDA-approved for the treatment of ADHD in persons ages 6 years and older), for the treatment of MCOS because of animal and human studies show that this drug induces endogenous BDNF levels. Atomoxetine could potentially increase hypothalamic BDNF levels, leading to weight loss through improved anorectic signaling downstream of the abnormally functioning MC4R. A phase 2 randomized, placebo-controlled crossover trial in 20 patients with MCOS will be conducted to test this hypothesis. The study will begin in adult patients and if safety and efficacy are shown, then pediatric patients age ≥ 6 years will be studied. The primary outcome measure will be change in BMI (expressed as the percentage of the 95th percentile BMI for age/sex). Additional measures will include percent body fat and visceral fat area by bioelectrical impedance analysis, resting energy expenditure by indirect calorimetry, dietary intake by food frequency questionnaire and 24-hour recall, hyperphagia score, hunger level, satiety level, hemoglobin A1c, lipid panel, liver function tests, blood pressure, heart rate, and ADHD symptoms. Serum and plasma BDNF and genetic variants in atomoxetine metabolism enzymes will be assessed and correlated with weight changes. This pilot clinical trial will provide valuable data on the safety and efficacy of atomoxetine for treating MCOS, and the data will be used to guide the design of a future phase 3, multicenter, randomized clinical trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- A randomized, placebo-controlled, crossover study of atomoxetine. The treatment periods will last 16 weeks, separated by a 2-week washout period. Atomoxetine immediate release is approved for treatment of ADHD in children and adults. Enrollment will be based on age groups in batches, beginning with 10 adults, to optimize the protocol and monitor safety/efficacy before treating younger patients. If safety and efficacy are acceptable, the pediatric cohort will be enrolled. The intervention length of 16 weeks per arm was chosen to allow for 4 weeks of dose titration and 12 weeks exposure to target dose. The FDA effectiveness threshold for anti-obesity medication is 5% weight loss after 12 weeks. The half-life of atomoxetine is approximately 5 hours. A two-week washout period will allow for elimination of study drug while minimizing participant burden from frequent study visits.
| Arm | Type | Receives |
|---|---|---|
| Placebo then Atomoxetine | Placebo comparator | Drug: Atomoxetine, Drug: PlaceboParticipants receive placebo for 16 weeks (4 weeks titration + 12 weeks at target dose), followed by washout period, then atomoxetine for 16 weeks (4 weeks titration + 12 weeks at target dose). |
| Atomoxetine then Placebo | Active comparator | Drug: Atomoxetine, Drug: PlaceboParticipants receive atomoxetine for 16 weeks (4 weeks titration + 12 weeks at target dose), followed by washout period, then placebo for 16 weeks (4 weeks titration + 12 weeks at target dose). |
Who may qualify
- Ages
- 6 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Age 6 years and above
- Documented MC4R variant classified as pathogenic, likely pathogenic, or variant of uncertain significance per ACMG criteria. If testing was done in a research lab, it will be confirmed by a CLIA-approved lab prior to randomization.
- Obesity defined as BMI ≥30 kg/m2 in adults or ≥95th percentile for age and sex in children
Key exclusion criteria (16 listed)
- Use of atomoxetine, viloxazine (another selective norepinephrine-reuptake inhibitor), methylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, phentermine, or any other stimulant medication in the past 30 days. If on other ADHD medications, such as guanfacine and clonidine, must be on a stable dose for >3 months.
- Weight loss >5% in the past 3 months.
- Initiation of new weight loss program, including diet or medications. If on weight loss medications, must be on a stable dose for >3 months.
- Inability to swallow capsules.
- History of hypersensitivity to atomoxetine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AtomoxetineInitial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose) | Drug | Atomoxetine then Placebo, Placebo then Atomoxetine |
| PlaceboMatching placebo oral capsule | Drug | Atomoxetine then Placebo, Placebo then Atomoxetine |
Primary outcome
Body Mass Index (BMI)
Time frame: 16 weeks
BMI will be calculated as kg/sq m. The sex appropriate CDC growth chart will be used to calculate BMI as a percent of the 95th percentile (BMI95). For patients >20 years, the 20-year-old percentiles will be used.
12 secondary outcomes
Resting Energy Expenditure (REE)
Time frame: 16 weeks
Healthy Eating Index (HEI)
Time frame: 16 weeks
Hyperphagia Questionnaire (HQ)
Time frame: 16 weeks
Hunger and Satiety Score
Time frame: 16 weeks
Fasting Glucose Level
Time frame: At week 0, week 16 and week 32.
Alanine Transaminase (ALT) Level
Time frame: At week 0, week 16 and week 32.
Fasting Insulin Level
Time frame: At week 0, week 16 and week 32.
Hemoglobin A1c
Time frame: At week 0, week 16 and week 32.
Lipid Panel - Fasting LDL, HDL, Triglycerides
Time frame: At week 0, week 16 and week 32.
High Sensitivity C-Reactive Protein
Time frame: At week 0, week 16 and week 32.
The ASEBA Brief Problem Monitor
Time frame: 16 weeks
Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist.
Time frame: 16 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Related trials for Melanocortin Obesity Syndrome
Active, not recruitingPhase 1/2
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Hypothalamic Obesity, Prader-Willi Syndrome
RecruitingPhase 4
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome
Active, not recruitingPhase 2
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joan C Han, MD principal investigator
Mount Sinai Kravis Children's Hospital
Ashley H Shoemaker, MD, MSCI principal investigator
Vanderbilt University Medical Center
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Atomoxetine in people with Melanocortin Obesity Syndrome and MCOS, run by Icahn School of Medicine at Mount Sinai at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joan C Han, MD (212-241-3744 ext. 301-312-7, joan.han@mountsinai.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body Mass Index (BMI) (time frame: 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.